These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10477909)

  • 1. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
    Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
    Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
    J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy.
    Milicević N; Mrcela M; Lukić I; Mandić S; Horvat V; Galić J
    Coll Antropol; 2014 Mar; 38(1):147-50. PubMed ID: 24851609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
    Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
    Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
    Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
    J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
    Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
    Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
    Chuang CK; Wu TL; Tsao KC; Liao SK
    J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
    Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
    J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
    Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
    BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.